58 results about "Infarction" patented technology

The invention discloses a hydrogel-acellular matrix composite patch containing functionalized extracellular vesicles and a preparation method of the hydrogel-acellular matrix composite patch. The composite patch comprises a hydrogel layer and an acellular pericardium matrix material layer, and an extracellular vesicle-macrophage membrane fusion body (EV-MM) is entrapped in the cross-linked hydrogel. From two aspects of improving the targeting of EVs to the cardiac infarction part and enhancing the retention of the EVs at the cardiac infarction part, the distribution condition of the EVs at the cardiac infarction part is improved, so that the action efficiency of the EVs is improved, and the treatment effect is improved.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention relates to an accurate evaluation and dynamic optimization system for cerebral infarction ultra-early reperfusion treatment, in particular to the field of biomedicine.Heterogeneous image data are fused through multi-center federal learning, and a high-robustness standardized brain characteristic spectrum is constructed; the real-time physiological parameters are utilized to drive the dynamic graph network, and the pathological process of the ischemic penumbra evolved along with time is accurately simulated; a core infarction zone and half-dark band probability graph with reasonable spatial distribution is generated by introducing a multi-task classifier with mutual exclusion constraints; and finally, a virtual contrast perfusion image is generated in combination with the individual blood vessel conditions of the patient to perform personalized calibration, so that the accuracy and individualization level of the delineation of the penumbra are remarkably improved, more reliable and dynamic decision support is provided for a clinician to formulate an ultra-early reperfusion treatment scheme, and the risk of insufficient treatment or excessive treatment is effectively avoided.

An apparatus for providing access to a patient's vasculature according to one aspect of the present invention comprises a dilator having a distal tip, a proximal end and a main body extending therebetween. The dilator includes a first lumen extending from the proximal end to the distal tip and a second lumen extending in parallel to the first lumen between the proximal end and a side port provided in the main body spaced proximal to the distal tip by a distance. The apparatus further comprises a first hemostasis valve in fluid communication with the first lumen at the proximal end of the dilator and a second hemostasis valve in fluid communication with the second lumen at the proximal end of the dilator. A retrograde guidewire is provided positionable within the first lumen of the dilator for advancement therein from the proximal end toward the distal tip and adapted to project therefrom by a first preselected distance. A deflection microcatheter is also provided positionable within the second lumen for advancement therein from the proximal end toward the side port and adapted to project therefrom by a second preselected distance and an antegrade guidewire positionable within a lumen of the deflection microcatheter for advancement therein from the proximal end toward the side port and adapted to project therefrom by a third preselected distance.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

The invention relates to the technical field of intelligent early warning, in particular to a wrist-wearing type acute infarction disease heart symptom home early warning system which comprises a signal alignment module, a feature association module, a trend recognition module, a risk triggering module and an event feedback module, and based on an electric pulse signal waveform, the occurrence time node of an R wave is judged to serve as a reference. Synchronous acquisition and unified time sequence processing of multichannel signals are realized, electrocardiogram, skin conductance and micro blood flow data are integrated on the basis of the same cardiac reference point, a time window-oriented multi-factor dynamic comparison structure is constructed, the trend relationship among multiple parameters is identified through correlation analysis, and the accuracy of the comparison result is improved. A threatened characteristic period is accurately positioned by means of a common pattern screening mechanism, real-time monitoring and historical comparison are integrated in a feedback process, data cyclic utilization is enhanced, multi-source signal dynamic collaborative judgment is realized, the timeliness and stability of risk identification are further improved, and the high-confidence early warning requirement of home health monitoring is effectively met.

The invention discloses an application of a Ptbp2 accelerant in treatment of cerebral arterial thrombosis. It is found for the first time that overexpressed Ptbp2 can remarkably improve the neurological function of a mouse with the cerebral arterial thrombosis, reduce the infarct volume and relieve neuroinflammation mediated by microglia, and the overexpressed Ptbp2 can be used for effective treatment of the cerebral arterial thrombosis. The invention provides a theoretical basis for research and development of drugs for treating cerebral arterial thrombosis, opens up the application of the Ptbp2 accelerant, provides a brand new method for treating cerebral arterial thrombosis, and has a wide application prospect in the technical field of cerebral arterial thrombosis treatment.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The invention discloses application of ellagic acid to prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition taking ellagic acid as a unique active ingredient or containing ellagic acid. According to the application of ellagic acid in prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the morbidity of myocardial infarction of a long-term simulated phreatic water rat model is reduced to 23.8% from 44.8% through ellagic acid administration, the infarction area is remarkably reduced to 4.6 + / -3.3% from 14.9 + / -7.7%, the right ventricular hypertrophy index is reduced to 23.3 + / -6.5% from 34.5 + / -12.2%, and the curative effect is remarkable. The ellagic acid can effectively prevent rat heart injury caused by long-term diving. Therefore, ellagic acid has a good application prospect in prevention of heart injury caused by long-term diving.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biology. A research result shows that in a mouse myocardial infarction model, compared with a control group mouse, the death rate of a myocardial cell specific Mboat7 gene overexpressed mouse is reduced, the infarction area is remarkably reduced, and the cardiac function is remarkably improved; the overexpressed Mboat7 gene can relieve mitochondrial damage of myocardial cells under the hypoxia condition and improve the mitochondrial oxidative phosphorylation function. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissues of mice suffering from myocardial infarction. The results show that Mboat7 gene overexpression can relieve myocardial damage after myocardial infarction so as to delay the progress of heart failure, and Mboat7 or an expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating myocardial infarction.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

To provide the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy.SOLUTION: In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, the patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.SELECTED DRAWING: None

This disclosure relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤20. In other embodiments, patients have lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

The invention belongs to the technical field of medicines, and finds an application of a compound esculetin as shown in a formula I and a precursor thereof in preparation of a medicine for promoting repair of dyskinesia and neurological impairment in a subacute stage-recovery stage after cerebral arterial thrombosis. It is found that the compound esculetin can significantly reduce the area and volume of infarction after cerebral arterial thrombosis and promote repair of dyskinesia and neurological impairment after cerebral arterial thrombosis, which is shown in improvement of sensory movement and posture asymmetry after cerebral arterial thrombosis and enhancement of forelimb movement function and limb coordination. The esculetin can be used for remarkably reducing neuron injury caused by cerebral ischemia. The compound can be used for preparing medicines for promoting the repair of dyskinesia and neurological function damage in the subacute stage-recovery stage after cerebral apoplexy.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

Disclosed are uses of a compound represented by general formula (I) and pharmaceutically acceptable salts, isomers and deuterated compounds thereof in the preparation of a medicine for treating heart failure diseases. Experiments prove that the compound can improve the heart function of rats with heart failure, reverse myocardial remodeling caused by heart failure, and reduce fibrosis in the marginal zone of infarction.

The invention discloses a multifunctional targeting hydrogel based on chiral polypeptide as well as a preparation method and application thereof, and the multifunctional targeting hydrogel based on chiral polypeptide comprises the following raw materials in parts by weight: targeting nanoparticles loaded with a TGF-beta inhibitor, chiral antioxidant polypeptide, a cross-linking agent and water. The multifunctional targeted hydrogel has the functions of MI early-stage efficient ROS removal and MI late-stage targeted fibrosis blocking, has the functions of remodeling the infarction area microenvironment, inhibiting scar tissue expansion and recovering cardiac muscle synchronous electrical conduction, and finally achieves coordination of hydrogel degradation kinetics and the heart repair process and multi-dimensional repair of damaged cardiac muscle.

The application discloses a new application of 3-HPPA in preparing a drug for treating myocardial infarction. By means of modern pharmacological research methods, it is first confirmed that 3-HPPA has a significant myocardial protective effect. Experimental research shows that 3-HPPA can significantly improve the heart function of a myocardial infarction mouse induced by coronary artery ligation, improve the left ventricular ejection fraction and the short axis shortening rate, and reduce the infarction area; meanwhile, 3-HPPA can significantly inhibit the gene expression of a heart failure marker BNP, and down-regulate the expression levels of inflammatory factors IL-6, TNF-alpha and fibrosis related factors TGF-beta and Collagen I. Further mechanism research shows that 3-HPPA also plays an anti-inflammatory, anti-fibrosis and anti-apoptosis role. The application discloses the action characteristics of 3-HPPA in multi-target intervention of the pathological process of myocardial infarction, provides an important candidate compound for development of a new type of anti-myocardial infarction drug, and has a wide clinical application prospect.

The invention relates to the technical field of medical images, and provides a method and equipment for reconstructing a personalized heart model with an infarction region, and a medium. The method comprises the following steps: preprocessing a heart magnetic resonance delay gadolinium enhanced CMR-LGE image of a patient to obtain a first high-resolution tag image containing a ventricular cavity and infarction tissue, and constructing a heart finite element mesh model based on high-precision heart cavity data of the patient; performing direction adjustment on the first high-resolution label image to obtain a second high-resolution label image; and mapping the infarction region in the second high-resolution label image into the heart finite element mesh model to obtain a personalized heart model with the infarction region. Based on the scheme of the invention, the accuracy of the reconstruction of the personalized heart model with the infarction region can be improved.

The application discloses a slow-release injectable conductive hydrogel and a preparation method and application thereof, and belongs to the technical field of biomedical materials, wherein the components of the slow-release injectable conductive hydrogel comprise crocetin modified by polyethylene glycol with different molecular weights, sodium alginate and bioactive glass; the crocetin modified by polyethylene glycol is prepared by an amidation reaction of crocetin and methoxypolyethylene glycol amine, and different molecular weight crocetin modified by polyethylene glycol is obtained by changing the molecular weight of the methoxypolyethylene glycol amine. The hydrogel can realize gradient slow release of the active ingredient crocetin, matches the conductivity with the natural myocardial tissue, can bridge the electrical signal conduction of the infarction area, realizes the electrophysiological-histological synergistic repair in the treatment of myocardial infarction, and provides an effective treatment strategy for the treatment of myocardial infarction.

The application discloses application of a resolution D2 in preparation of a medicine for relieving and / or treating myocardial infarction and related diseases, and belongs to the technical field of medicines. The application finds that the resolution D2 has the effects of improving myocardial infarction and reducing myocardial remodeling after the infarction, and the resolution D2 can be used as an active ingredient to prepare the medicine for relieving and / or treating myocardial infarction and related diseases. The application finds the function of the resolution D2 in improving myocardial remodeling after myocardial infarction, and provides a target for developing a new medicine for relieving and / or treating myocardial infarction and related diseases.

An apparatus for providing access to a patient's vasculature comprises a dilator having a first lumen extending from a proximal end to a distal tip and a second lumen extending in parallel to the first lumen between the proximal end and a side port provided in the main body spaced proximal to the distal tip by a distance. The apparatus further comprises a first and second hemostasis valves in fluid communication with the proximal ends of the first and second lumens, respectively. A retrograde guide wire is provided positionable within the first lumen of the dilator and adapted to project from the distal tip by a first preselected distance. A deflection microcatheter is also provided positionable within the second lumen and adapted to project from the side port by a second preselected distance and an antegrade guide wire positionable within a lumen of the deflection microcatheter and adapted to project from the side port by a third preselected distance.

The application relates to the field of biological medicine, and particularly discloses a fusion protein and application thereof. The fusion protein is composed of a polypeptide and six histidines, the polypeptide has sequence consistency of at least 9 / 10, 14 / 15 or 29 / 30 with the amino acid sequence shown in SEQ ID NO:1, and the six histidines are located at the C-terminal of the polypeptide. The fusion protein designed in the application is derived from a human body protein, the metabolic product is an amino acid, and therefore the safety is better than that of other therapeutic drugs. Moreover, the fusion protein can significantly reduce the infarction volume of the brain of a tMCAO model mouse, has a significant treatment on ischemic stroke, and has a longer treatment time window than that of an existing thrombolytic drug. Compared with the existing ischemic stroke treatment drug, the human sTREM2-6His fusion protein has a brand-new treatment mechanism and target.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention discloses an application of a mitochondria-rich cell disintegration body in treatment of myocardial ischemia reperfusion injury. The invention provides an application of a mitochondrial-rich cell disintegration body in preparation of a product for preventing and / or treating myocardial ischemia-reperfusion injury. The cell disintegration body is extracted from mitochondrial donor cells treated by cytochalasin D. The invention further provides a preparation method of the mitochondrial-rich cell disintegration body. The mitochondrial-rich cell disintegration body has ultrahigh mitochondrial loading capacity and functional activity and excellent in-vivo and in-vitro stability; the functional mitochondria can be efficiently delivered to a heart injury area, the myocardial protection effect is achieved by activating an endothelial cell autophagy pathway, the heart function is remarkably improved, the infarct area is reduced, and the good clinical application prospect is achieved.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 300 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate of <25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating